Consistent Alterations of Circulating Matrix Metalloproteinases Levels in Untreated Hypertensives and in Spontaneously Hypertensive Rats: A Relevant Pharmacological Target

Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients

(2011) R Lacchini et al.   JOURNAL OF HUMAN HYPERTENSION

Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension

(2010) CS Ceron et al.   BRITISH JOURNAL OF PHARMACOLOGY

Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients

(2010) Riccardo Lacchini et al.   CLINICA CHIMICA ACTA

Matrix Metalloproteinase Inhibition Improves Cardiac Dysfunction and Remodeling in 2-Kidney, 1-Clip Hypertension

(2010) Élen Rizzi et al.   JOURNAL OF CARDIAC FAILURE

Enhanced Matrix Metalloproteinase Activity in the Spontaneously Hypertensive Rat: VEGFR-2 Cleavage, Endothelial Apoptosis, and Capillary Rarefaction

(2010) Edward D. Tran et al.   JOURNAL OF VASCULAR RESEARCH

Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix

(2009) A. D. Kandasamy et al.   CARDIOVASCULAR RESEARCH

Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome

(2009) Flavia M. Gonçalves et al.   CLINICA CHIMICA ACTA

Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy

(2009) Andrea M. Marcaccini et al.   CLINICA CHIMICA ACTA

Matrix Metalloproteinases: Discrete Elevations in Essential Hypertension and Hypertensive End-Stage Renal Disease

(2009) Ryan S. Friese et al.   CLINICAL AND EXPERIMENTAL HYPERTENSION

Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents

(2009) Vanessa A. Belo et al.   CLINICAL BIOCHEMISTRY

Positive correlations between serum and plasma matrix metalloproteinase (MMP)-2 or MMP-9 levels in disease conditions

(2009) Raquel F. Gerlach et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling

(2009) Michele M. Castro et al.   MATRIX BIOLOGY

Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension

(2008) Ana C.T. Palei et al.   CLINICAL BIOCHEMISTRY

Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment

(2008) Ibrahim Koral Onal et al.   European Journal of Internal Medicine

Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats

(2008) Marcio L.L. Martinez et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats

(2008) Marcio L.L. Martinez et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Increased Matrix Metalloproteinase 2 Activity in the Human Internal Mammary Artery Is Associated with Ageing, Hypertension, Diabetes and Kidney Dysfunction

(2008) A.W. Chung et al.   JOURNAL OF VASCULAR RESEARCH

Differences in both matrix metalloproteinase 9 concentration and zymographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices

(2007) Ferdinando Mannello et al.   ANALYTICAL BIOCHEMISTRY

Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats

(2007) Michele M. Castro et al.   ATHEROSCLEROSIS

Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease

(2007) Joseph D. Raffetto et al.   BIOCHEMICAL PHARMACOLOGY